相关临床试验
37
13 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1946
进行中（未招募）
2
5.4%
已完成
15
40.5%
尚未招募
11
29.7%
招募中
7
18.9%
撤回
2
5.4%
暂无批准数据
- Analysis of two ancient skeletons from Sulawesi, Indonesia, found traces of the psychoactive compound arecoline in teeth, dating human drug use back as far as 25,000 years. - The individuals show distinctive tooth grooves consistent with repeatedly sucking on betel nuts, predating the oldest known drug-use evidence by at least 3,000 years. - Researchers confirmed the mechanism experimentally by soaking betel nuts in artificial saliva and testing the extract on frog egg cells engineered with human brain receptors. - The findings suggest betel nut sucking may have served as a painkiller, creating a self-perpetuating cycle of tooth damage and addiction.
- Griffith University researchers announced successful Phase II trial results for STC3141, a carbohydrate-based drug candidate targeting sepsis, one of the leading causes of death globally. - The small-molecule experimental drug, administered via infusion, met key endpoints by successfully reducing sepsis in humans and works by counteracting harmful biological molecule release during sepsis. - Currently no specific anti-sepsis therapy exists, representing a significant clinical unmet need as sepsis affects millions of hospitalized patients annually through immune system attacks on body tissues. - Grand Pharmaceutical Group Limited conducted the trial, which now paves the way for Phase III testing with potential market availability within a few years.
- Medibank, Australia's largest private health insurer, has entered a multi-year partnership with Emyria to fund the Empax PTSD care program, marking the first time a major private health insurer has funded an ethics-approved, psychiatrist-led trauma therapy program. - Eligible Medibank members can now access the comprehensive trauma care program with no out-of-pocket costs at Perth Clinic, with treatment typically valued between AUD $20,000 and AUD $30,000. - The Empax model integrates psychiatrist-supervised therapy, specialist care coordination, and continuous real-world data collection, addressing the urgent need for innovative mental health treatments as PTSD affects approximately one in 11 Australians. - Independent evaluation by Professor Paul Fitzgerald from Australian National University will assess clinical effectiveness and health economics to build the case for broader reimbursement and systemic adoption.
